Estimating the cost-effectiveness of the Sodium Reduction in Communities Program.


Journal

Public health nutrition
ISSN: 1475-2727
Titre abrégé: Public Health Nutr
Pays: England
ID NLM: 9808463

Informations de publication

Date de publication:
04 2022
Historique:
pubmed: 26 10 2021
medline: 6 4 2022
entrez: 25 10 2021
Statut: ppublish

Résumé

This study assessed the cost-effectiveness of the Centers for Disease Control and Prevention's (CDC's) Sodium Reduction in Communities Program (SRCP). We collected implementation costs and performance measure indicators from SRCP recipients and their partner food service organisations. We estimated the cost per person and per food service organisation reached and the cost per menu item impacted. We estimated the short-term effectiveness of SRCP in reducing sodium consumption and used it as an input in the Prevention Impact Simulation Model to project the long-term impact on medical cost savings and quality-adjusted life-years gained due to a reduction in CVD and estimate the cost-effectiveness of SRCP if sustained through 2025 and 2040. CDC funded eight recipients as part of the 2016-2021 round of the SRCP to work with food service organisations in eight settings to increase the availability and purchase of lower-sodium food options. Eight SRCP recipients and twenty of their partners. At the recipient level, average cost per person reached was $10, and average cost per food service organisation reached was $42 917. At the food service organisation level, median monthly cost per food item impacted by recipe modification or product substitution was $684. Cost-effectiveness analyses showed that, if sustained, the programme is cost saving (i.e. the reduction in medical costs is greater than the implementation costs) in the target population by $1·82 through 2025 and $2·09 through 2040. By providing evidence of the cost-effectiveness of a real-world sodium reduction initiative, this study can help inform decisions by public health organisations about related CVD prevention interventions.

Identifiants

pubmed: 34693898
pii: S1368980021004419
doi: 10.1017/S1368980021004419
pmc: PMC8957494
mid: NIHMS1750632
doi:

Substances chimiques

Sodium, Dietary 0
Sodium 9NEZ333N27

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1050-1060

Subventions

Organisme : Intramural CDC HHS
ID : HHSD2002013M53964B
Pays : United States

Références

Am Heart J. 1991 Jan;121(1 Pt 2):293-8
pubmed: 1985385
N Engl J Med. 2014 Aug 28;371(9):796-7
pubmed: 25162885
Prev Chronic Dis. 2021 Feb 04;18:E09
pubmed: 33544072
Circulation. 2014 Mar 4;129(9):981-9
pubmed: 24415713
Am J Clin Nutr. 1997 Feb;65(2 Suppl):643S-651S
pubmed: 9022560
Ann Intern Med. 2010 Apr 20;152(8):481-7, W170-3
pubmed: 20194225
Prev Chronic Dis. 2019 Jul 03;16:E87
pubmed: 31274409
Am J Cardiol. 1998 May 1;81(9):1110-5
pubmed: 9605051
Hypertension. 2013 Mar;61(3):564-70
pubmed: 23399718
Prev Med. 2019 Mar;120:100-106
pubmed: 30659909
Pediatrics. 2012 Oct;130(4):611-9
pubmed: 22987869
BMC Cardiovasc Disord. 2016 Jan 14;16:13
pubmed: 26769473
Am J Public Health. 2014 Jul;104(7):1187-95
pubmed: 24832142
JAMA. 2018 Mar 27;319(12):1209-1220
pubmed: 29516104
PLoS One. 2015 Apr 24;10(4):e0123915
pubmed: 25910259
Int J Epidemiol. 2017 Oct 1;46(5):1551-1405
pubmed: 28204481
J Hum Hypertens. 2002 Nov;16(11):761-70
pubmed: 12444537
Prev Chronic Dis. 2010 Jan;7(1):A18
pubmed: 20040233
BMJ. 2013 Apr 03;346:f1326
pubmed: 23558163
Am J Health Promot. 2009 Jul-Aug;23(6):412-22
pubmed: 19601481
Prev Chronic Dis. 2008 Apr;5(2):A63
pubmed: 18341798
Am J Public Health. 2010 Apr;100(4):590-5
pubmed: 20167880
Br J Nutr. 2014 Feb;111(4):662-71
pubmed: 24326147
Healthc Financ Manage. 1995 Feb;49(2):50-2, 54-6
pubmed: 10146178
Nutr J. 2016 Apr 26;15:44
pubmed: 27118548
Prev Chronic Dis. 2016 Apr 07;13:E47
pubmed: 27055264
JAMA. 1996 May 22-29;275(20):1590-7
pubmed: 8622251
PLoS One. 2013 Oct 10;8(10):e75289
pubmed: 24130700
Am J Health Promot. 2009 Sep-Oct;24(1):49-57
pubmed: 19750962
Am J Cardiol. 2000 Jul 1;86(1):17-23
pubmed: 10867086
J Hum Hypertens. 2008 Jan;22(1):4-11
pubmed: 17823599
N Engl J Med. 2010 Feb 18;362(7):590-9
pubmed: 20089957
JAMA. 2001 Jun 20;285(23):2981-6
pubmed: 11410096
Am J Public Health. 2010 Apr;100(4):616-22
pubmed: 20167899
Cochrane Database Syst Rev. 2013 Apr 30;(4):CD004937
pubmed: 23633321
Prev Chronic Dis. 2020 Jul 30;17:E72
pubmed: 32730201

Auteurs

Benjamin Yarnoff (B)

RTI International, Research Triangle Park, NC27709, USA.

Emily Teachout (E)

Centers for Disease Control and Prevention, Atlanta, GA, USA.
Deloitte Consulting, LLP, London, UK.

Kara MacLeod (K)

Centers for Disease Control and Prevention, Atlanta, GA, USA.
IHRC, Inc., Atlanta, GA, USA.

John Whitehill (J)

Centers for Disease Control and Prevention, Atlanta, GA, USA.

Julia Jordan (J)

Centers for Disease Control and Prevention, Atlanta, GA, USA.

Zohra Tayebali (Z)

RTI International, Research Triangle Park, NC27709, USA.

Laurel Bates (L)

RTI International, Research Triangle Park, NC27709, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH